Table 2. Results of univariate and multivariate analyses.
| Patient characteristics | Univariate analysis HR (95% CI) | P-value | Multivariate analysis (P-value) |
|---|---|---|---|
| C/EBP β | 0. 392 (0.201–0.764) | 0.006 | 0.046 |
| Tumor side | 1.33 (0.706–2.504) | 0.378 | — |
| RFS | 0.554 (0.49–0.625) | 0.001 | — |
| Age (years) | 1.067 (1.038–1.096) | 0.001 | 0.001 |
| Menopausal status | 1.002 (1–1.003) | 0.013 | 0.419 |
| Chemotherapy | 1.447 (0.703–2.979) | 0.316 | — |
| Endocrine therapy | 0.778 (0.402–1.505) | 0.456 | — |
| Tumor size | 1.018 (1.009–1.028) | 0.001 | — |
| Lymph node status | 1.961 (1.295–2.969) | 0.001 | 0.05 |
| HER2 status | 1.64 (1.223–2.198) | 0.001 | 0.422 |
| ER status | 0.39 (0.19–0.802) | 0.01 | 0.097 |
| PR status | 0.419 (0.223–0.786) | 0.07 | — |
| Luminal A | 0.319 (0.165–0.617) | 0.001 | 0.413 |
| Luminal B | 3.802 (1.342–10.77) | 0.012 | 0.175 |
| Basal (triple negative) | 2.039 (0.897–4.632) | 0.089 | — |
Abbreviations: C/EBPβ, CCAAT-enhancer binding protein β CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; PR, progesterone receptor; RFS, relapse-free survival. Bold and italic numerals mark probability that was considered statistically significant (P<0.05).